Oxford, United Kingdom
Evox Therapeutics Ltd, established in 2016, is at the forefront of innovative biopharmaceutical development, particularly focusing on the central nervous system (CNS). Their slogan, "Changing the course of CNS disease," accurately reflects their groundbreaking work with extracellular vesicles, a novel class of biotherapeutics. This approach synthesizes pioneering exosome technology developed in collaboration with renowned institutions such as Oxford University and the Karolinska Institutet.
With headquarters in the United Kingdom, Evox is a powerhouse, assembling an extensive intellectual property portfolio that enhances their pivotal role in both biotechnology and pharmaceutical industries. Their recent £69.20M Series C investment announced on February 18, 2021, reflects strong confidence from key investors, including GV, OrbiMed, Invus, Redmile Group, Cowen Digital, Eli Lilly, and Oxford Science Enterprises. With a robust team and proprietary technology platforms, Evox is poised to revolutionize therapeutic treatment across multiple severe disease domains.
